Furthermore, a recent article published by Schnell et al also pointed towards the potential of PGLYRP1 as a novel target for immunotherapy in cancer, as apart from reducing tumour size in other cancer models, its targeting did not generate autoimmune neuroinflammation.32 In addition, from a clinical point of view and supported by our results, PGLYRP1 could also be useful as a biomarker for patient stratification. Here, PGLYRP1 is linked to cancer.